Follow us on Facebook  Follow us on Twitter  Investors Hub Board
Wall Street Newscast  Where Wall Street Listens

Join Our Email List
Email:  

Home | Email Alerts | Message Board | Twitter | Awareness Services | Contact
stock picks



PuraMed BioScience, Inc (OTC:PMBS)
1326 Schofield Avenue
Schofield, WI 54476
Phone: 715-359-6373
Email: info@southstreetmedia.com 
Real-Time Quote

PMBS Mailing List

PMBS Message Board



About PuraMed BioScience, Inc.

PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic M, PuraMed BioScience plans to launch LipiGesic H for tension-type headaches as well as LipiGesic PM, which provides a remedy for insomnia and other sleep disorders. For more information visit www.puramedbioscience.com


Shares Authorized:  Public Float: UR
Shares Outstanding: 250 million Price Target: $0.02+

*
based on OTC Markets data


PMBS Marijuana Dispensaries Deal Could Spell End to Toxic Financing
Last Updated:
Dec. 11, 2014 - 4:30pm EST

(NEW YORK)--PuraMed BioScience, Inc. (OTC:PMBS), a developer of over-the-counter health and wellness products, announced distribution funding deal that could spell higher prices for their stock.

Under the distribution agreement, PMBS will gain access for their MigraPure H migraine headache product to 1,000 marijuana dispensaries, and other distribution venues throughout Colorado, Washington State, and California.

End of Toxic Financing

The distribution deal to 1000 marijuana dispensaries is exciting in itself, but what market should really make note of is that this could spell the end of toxic financing for the company, and could allow for higher share price.

For anyone that has followed PMBS the main issue with the Company has been the issue of legacy convertible debt, which as many small-cap traders know can become extremely dilutive for lower priced stocks.

Under this current distribution agreement though, PMBS is receiving funding to launch product out to the 1000 dispensaries under an exclusive rights agreement for a cut of the action, not toxic convertible debt. This is a major development for PMBS as this now removes the extreme overhang of aged debt, and reduces prospects of sharp share dilution moving forward.

The Company may still have roughly $100,000 of older aged debt to work through in the coming months with Magna Equities, but with non-toxic funding in place, access to 1000 marijuana dispensaries, product expected on shelves in early 2015, and only 215 million outstanding, PMBS could provide some real value for traders as stock current trades at a market cap of only $65,000.

Yes, you read that correct, market cap is only $65,000 at $0.0003 per share.





Safe Harbor Statements:

This investor presentation may include statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.

Disclaimer
:

This is NOT a solicitation to Buy or Sell any security, but rather is for informational purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Wall Street Newscast ("WSNC") does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. WSNC, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encourage to consider this as a possible conflict of interest when reviewing this information. In Compliance with SEC Rule 17B Wall Street Newscast was compensated two million restricted common shares for research and media alert. WSNC may hold a position in above securities from time to time, and thus should be considered a possible conflict of interest when reviewing this report and information. These investments may involve a high degree of risk, thus investors are highly encouraged to consult with a financial advisor before any and all investments.

Your use of this website is subject to our terms & conditions. Wall Street Newscast 1998 - 2011

This website includes statements that may constitute forward-looking statements made pursuant to the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the
expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements
are subject to risks and uncertainties that could cause actual results to differ materially from those projected.